Programme 1 – ThARGET

The SIRIC ILIAD Partners Committee met on Monday 17 October 2022 to present the results of the 5 years of labelling. A week ago, the fifth meeting of the SIRIC ILIAD Partners Committee took place [...]

A film on the Nantes nuclear medicine cluster is being shown throughout the SNMMI international congress being held in Vancouver from 11 to 14 June 2022. From bench to bedside: The uniqueness and [...]

In January 2022, at the end of its five-year mandate, the CRCINA (Centre de Recherche en Cancérologie et Immunologie Nantes – Angers) evolves and becomes the CRCI²NA. Philippe Juin and [...]

At the beginning of 2022, the ThARGET programme teams of SIRIC ILIAD are now partners in the Hospital-University Health Research (RHU) project OPERANDI led by Professor Valérie Vilgrain of the [...]

Following the mid-term evaluation of the SIRICs (SIte de Recherche Intégrée sur le Cancer), the scientific committee of the French National Cancer Institute (INCa) underlines in its scientific [...]

Following the installation of new Siemens imaging equipment at the Nantes University Hospital last May, the public-private partnership between Siemens and the University Hospital has reached a [...]

Interdisciplinary School In Nuclear Medicine (ISI NucMed) 2022 Arronax organises the Interdisciplinary School (ISI) In Nuclear Medicine (NucMed) from 27 to 29 June 2022. Over three days, 35 [...]

Video : Introduction to SIRIC ILIAD’s research work on breast cancer The SIRIC ILIAD Nantes-Angers (Integrated Cancer Research Site) was certified in December 2017 by INCa, and has been [...]

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer : The OPALESCENCE study, a collaborative research project with the ICO, Telix and the SIRIC ILIAD. MELBOURNE, [...]

Nantes research on astatine in the spotlight Astatine (At) is the rarest chemical element on Earth, and its 211 isotope is very promising for applications in targeted radiotherapy of cancers. [...]